explore -WSS

explore

author：comprehensive 2025-10-01 02:13:03 - browse：4

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourlais, unfortunately, the worst.

My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.

Pfizer shares have fallen 50% this year to their lowest level in more than a decade, erasing nearly $140 billion in market value. In 2022, the company delivered $100 billion in revenue, boosted by a widely used Covid vaccine and Covid treatment. This year, Covid product sales evaporated — and will fall further next year — leaving a vacuum Pfizer is struggling to fill with aging medicines nearing the end of their patent lives, and newer drugs and vaccines that have not performed as expected.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Weight loss drugs aren’t covered by Obamacare. That may change

WSS

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

To bolster infectious disease surveillance, genomics powerhouses team up

Surprise medical billing ban raises prices elsewhere

Measles policy set amid Florida outbreak alarms vaccine proponents

FDA sets aggressive timeline for overhauling inspection procedures

MD Anderson's Padmanee Sharma responds to research credit suit

knowledge

explore

Wikipedia

Hollywood unions extend contract negotiations for actors

Update the Apgar Score to remove skin color

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA sets aggressive timeline for overhauling inspection procedures

Tori Bowie and the unacceptable rates of Black maternal death

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Supreme Court strikes down use of affirmative action

Opioid cravings were reduced by anti

Drug repurposing or repositioning? The language matters

High breast density mammograms need follow

knowledge

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Printout prescription drug information shouldn’t go digital

TikTok, Instagram influencers need more rules for drug ads

Abridge raises $150m as clinical notes automation market heats up

Weight loss drugs aren’t covered by Obamacare. That may change

Mass General, Mayo Clinic look to monetize custom

explore

Wikipedia

hotspot

knowledge